PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025

Market: Pharmaceuticals and Healthcare

Global, 419 pages report, published by GlobalData

Report ThumbnailNovember-2016
PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025

Summary

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

Today, available vaccines include the older egg-based, adjuvanted and non- adjuvanted inactivated vaccines, along with live-attenuated vaccines and newer, cell culture-based seasonal influenza vaccines. Within these four vaccine classes, continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. The anticipated launch of quadrivalent, cell culture-based VLP vaccines will have the potential to revolutionize the approaches used to protect against seasonal influenza infections. GlobalData expects the global seasonal influenza vaccines market - which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) - to grow moderately during the next decade at a CAGR of 3.3%, reaching total sales of $4.3 billion by 2025.

Highlights

Key Questions Answered

- Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the seasonal influenza vaccine marketplace.
- What will be the effect of recent and upcoming changes in national immunization schedules?
- How will the upcoming first-in-class Virus-Like Particle (VLP) vaccine be received in the different markets?
- What research and development (R&D) strategies will companies leverage to compete in the future seasonal influenza vaccine marketplace?
- Which patient population(s) are most likely to be targeted by seasonal influenza vaccines?

Key Findings

- GlobalData has calculated that the global seasonal influenza vaccine market generated about $3.1 billion in sales in 2015. This global market is expected to grow modestly at a Compound Annual Growth Rate (CAGR) of 3.3%, reaching sales of $4.3 billion by 2025. The majority of this growth will occur in the 5EU, driven by the uptake of egg-based, quadrivalent vaccines. Further growth is anticipated due to the launch of cell-culture. quadrivalent vaccines in the 7MM. The seasonal influenza vaccines market in the 5EU is expected to grow at a CAGR of 5.5%, reaching sales of $1 billion by 2025. GlobalData estimates sales in the US to grow moderately at a CAGR of 3.5% during the next 10 years, reaching $2.6 billion by 2025, while Japan will experience marginal growth, with a CAGR of 0.3%.
- KOLs interviewed by GlobalData repeatedly identified the effectiveness of seasonal influenza vaccines as the number one unmet need. They argued that the influenza virus rapid antigenic drift coupled to a time-consuming egg-based vaccine manufacturing approach are barriers to increasing vaccine efficacy and duration.
- GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, pathophysiology, as well current routine seasonal influenza vaccine recommendations of all 7MM covered.
- Top-line seasonal influenza vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the seasonal influenza vaccine market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global seasonal influenza vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global seasonal influenza vaccine market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seasonal influenza vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • 1.2 List of Figures
  • Figure 1: Influenza Virus Structure 30
  • Figure 2: 7MM, Cases with Seasonal Influenza Vaccination, All Ages, Both Sexes, N, 2015-2025 64
  • Figure 3: 7MM, Age-Specific Cases with Seasonal Influenza Vaccination, Both Sexes, N, 2015 66
  • Figure 4: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N, 2015 68
  • Figure 5: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, 2015-2025 70
  • Figure 6: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015 71
  • Figure 7: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 74
  • Figure 8: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N, 2015 76
  • Figure 9: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N, 2015 78
  • Figure 10: 7MM, Age-Standardized Diagnosed Outpatient ILI Incidence, All Ages, Cases per 100,000 Population, 2015 79
  • Figure 11: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025 81
  • Figure 12: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N, 2015 83
  • Figure 13: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N, 2015 85
  • Figure 14: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 87
  • Figure 15: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N, 2015 89
  • Figure 16: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, N, 2015 91
  • Figure 17: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025 93
  • Figure 18: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N, 2015 95
  • Figure 19: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016 251
  • Figure 20: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025 252
  • Figure 21: Company Portfolio Gap Analysis in Seasonal Influenza Vaccines, 2015-2025 289
  • Figure 22: Global (7MM) Sales for Seasonal Influenza Vaccines by Country, 2015 and 2025 312
  • Figure 23: Sales of Seasonal Influenza Vaccines by Class in the US, 2015 and 2025 320
  • Figure 24: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025 326
  • Figure 25: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025 331
  • Figure 26: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025 336
  • Figure 27: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025 342
  • Figure 28: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025 347
  • Figure 29: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025 353
  • 1.1 List of Tables
  • Table 1: Notable Influenza Pandemics 33
  • Table 2: Influenza Symptoms 35
  • Table 3: Risk Factors and Comorbidities for Seasonal Influenza 38
  • Table 4: 7MM, Historical Perspective of Seasonal Influenza Vaccination Coverage 41
  • Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Total Population Vaccination Rates of Seasonal Influenza 44
  • Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Outpatient Seasonal ILI 45
  • Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Laboratory Confirmed Incident Cases of Seasonal Influenza 46
  • Table 8: 7MM, Sources of Epidemiological Data Used to Forecast Seasonal Influenza-Related Hospitalized Incident Cases 47
  • Table 9: 7MM, Sources of Epidemiological Data Used to Forecast Averted Cases of Seasonal Influenza 48
  • Table 10: 7MM, Sources Not Used in Epidemiological Analysis of Seasonal Influenza 62
  • Table 11: 7MM, People Receiving Seasonal Influenza Vaccination, All Ages, Both Sexes, N, Selected Years 2015-2025 64
  • Table 12: 7MM, Age-Specific Distribution of People Receiving Seasonal Influenza Vaccination, Both Sexes, N (Row %), 2015 65
  • Table 13: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N (Row %), 2015 67
  • Table 14: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, Selected Years 2015-2025 69
  • Table 15: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015 71
  • Table 16: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 73
  • Table 17: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N (Row %), 2015 75
  • Table 18: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N (Row %), 2015 77
  • Table 19: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025 80
  • Table 20: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N (Row %), 2015 82
  • Table 21: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N (Row %), 2015 84
  • Table 22: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 86
  • Table 23: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N (Row %), 2015 88
  • Table 24: 7MM, Influenza Related Hospitalized Incident Cases, All Ages, N (Row %), 2015 90
  • Table 25: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025 92
  • Table 26: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N (Row %), 2015 94
  • Table 27: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016 99
  • Table 28: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016 101
  • Table 29: Country Profile - US 102
  • Table 30: Country Profile - France 108
  • Table 31: Country Profile - Germany 113
  • Table 32: Country Profile - Italy 118
  • Table 33: Country Profile - Spain 124
  • Table 34: Country Profile - UK 129
  • Table 35: Country Profile -Japan 134
  • Table 36: Leading Seasonal Influenza Vaccines, 2016 139
  • Table 37: Product Profile - Fluzone Quadrivalent 141
  • Table 38: Immunogenicity Profile of Fluzone Quadrivalent 142
  • Table 39: Local and Systemic AEs of Fluzone Quadrivalent 143
  • Table 40: Fluzone Quadrivalent SWOT Analysis, 2016 144
  • Table 41: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025 146
  • Table 42: Product Profile - Fluzone High-Dose 147
  • Table 43: Immunogenicity of Fluzone High-Dose Compared with Fluzone 149
  • Table 44: Local and Systemic AEs of Fluzone High-Dose 150
  • Table 45: Fluzone High-Dose SWOT Analysis, 2016 151
  • Table 46: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025 153
  • Table 47: Product Profile - Fluzone Intradermal 155
  • Table 48: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent 157
  • Table 49: Local andsystemic AEs of Fluzone Intradermal Quadrivalent 158
  • Table 50: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016 159
  • Table 51: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025 161
  • Table 52: Product Profile - Vaxigrip 163
  • Table 53: Cumulative Incidence of Influenza Infection in Children 164
  • Table 54: Local and Systemic AEs of Vaxigrip 165
  • Table 55: Vaxigrip SWOT Analysis, 2016 165
  • Table 56: Global Sales Forecast ($m) for Vaxigrip, 2015-2025 167
  • Table 57: Product Profile - Fluarix Tetra 169
  • Table 58: Immunogenicity Profile of Fluarix Tetra 170
  • Table 59: Local and Systemic AEs of Fluarix Tetra 171
  • Table 60: Fluarix Tetra SWOT Analysis, 2016 172
  • Table 61: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025 174
  • Table 62: Product Profile - Fluvirin 175
  • Table 63: Immunogenicity of Fluvirin in Adults 176
  • Table 64: Local and Systemic AEs of Fluvirin 177
  • Table 65: Fluvirin SWOT Analysis, 2016 178
  • Table 66: Global Sales Forecast ($m) for Fluvirin, 2015-2025 179
  • Table 67: Product Profile - Afluria 180
  • Table 68: Immunogenicity of Afluria in Adults 181
  • Table 69: Local and Systemic AEs of Afluria 182
  • Table 70: Afluria SWOT Analysis, 2016 183
  • Table 71: Global Sales Forecast ($m) for Afluria, 2015-2025 184
  • Table 72: Product Profile - Agrippal 186
  • Table 73: Immunogenicity of Agrippal 187
  • Table 74: Local and Systemic AEs of Agrippal 187
  • Table 75: Agrippal SWOT Analysis, 2016 188
  • Table 76: Global Sales Forecast ($m) for Agrippal, 2015-2025 189
  • Table 77: Product Profile - Fluad 191
  • Table 78: Immunogenicity Comparison of Fluad Versus Agriflu 192
  • Table 79: Local and Systemic AEs of Fluad 193
  • Table 80: Fluad SWOT Analysis, 2016 194
  • Table 81: Global Sales Forecast ($m) for Fluad, 2015-2025 196
  • Table 82: Product Profile - FluMist Quadrivalent 198
  • Table 83: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent 200
  • Table 84: AEs of FluMist Quadrivalent 201
  • Table 85: FluMist Quadrivalent SWOT Analysis, 2016 201
  • Table 86: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025 203
  • Table 87: Product Profile - Flublok 205
  • Table 88: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose 207
  • Table 89: Local and Systemic AEs of Flublok 208
  • Table 90: Flublok SWOT Analysis, 2016 209
  • Table 91: Global Sales Forecast ($m) for Flublok, 2015-2025 211
  • Table 92: Product Profile - Flucelvax 213
  • Table 93: Immunogenicity of Flucelvax 214
  • Table 94: Local and Systemic AEs of Flucelvax 215
  • Table 95:Flucelvax SWOT Analysis, 2016 216
  • Table 96: Global Sales Forecast ($m) for Flucelvax, 2015-2025 218
  • Table 97: Summary of Other Marketed Seasonal Influenza Vaccines, 2016 220
  • Table 98: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016 224
  • Table 99: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016 251
  • Table 100: Quadrivalent Versions of Marketed Vaccines 254
  • Table 101: Product Profile - Seasonal Influenza VLP Vaccine 257
  • Table 102: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 262
  • Table 103: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025 264
  • Table 104: Product Profile - VN-100 266
  • Table 105: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine 267
  • Table 106: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine 268
  • Table 107: VN-100 SWOT Analysis, 2016 271
  • Table 108: Global Sales Forecast ($m) for VN-100, 2015-2025 272
  • Table 109: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine 274
  • Table 110: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 278
  • Table 111: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025 280
  • Table 112: Promising Vaccines in Early-Stage Development, 2016 281
  • Table 113: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016 284
  • Table 114: Key Companies in the Seasonal Influenza Vaccines Market, 2016 288
  • Table 115: Sanofi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 293
  • Table 116: CSL Limited’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 295
  • Table 117: GSK’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 297
  • Table 118: AstraZeneca’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 299
  • Table 119: Protein Sciences Corporation’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 301
  • Table 120: Mitsubishi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 303
  • Table 121: Novavax’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 305
  • Table 122: Global (7MM) Sales Forecasts ($m) for Seasonal Influenza Vaccines, 2015-2025 310
  • Table 123: Seasonal Influenza Vaccines Market - Drivers and Barriers, 7MM, 2015-2025 313
  • Table 124: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the US, 2015-2025 319
  • Table 125: Key Events Impacting Sales for Seasonal Influenza in the US, 2015‒2025 321
  • Table 126: US Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 322
  • Table 127: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 -2025 325
  • Table 128: Key Events Impacting Sales for Seasonal Influenza in France, 2015‒2025 327
  • Table 129: France Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 327
  • Table 130: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 -2025 330
  • Table 131: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015‒2025 332
  • Table 132: Germany Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 332
  • Table 133: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015-2025 335
  • Table 134: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015‒2025 337
  • Table 135: Italy Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 338
  • Table 136: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 -2025 341
  • Table 137: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015‒2025 343
  • Table 138: Spain Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 343
  • Table 139: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015-2025 346
  • Table 140: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015‒2025 348
  • Table 141: UK Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 349
  • Table 142: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015-2025 352
  • Table 143: Key Events Impacting Sales for Seasonal Influenza in Japan 2015‒2025 354
  • Table 144: Japan Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 355
  • Table 145: Key Launch Dates 400
  • Table 146: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 414
  • 1 Table of Contents
  • 1 Table of Contents 10
  • 1.1 List of Tables 17
  • 1.2 List of Figures 24
  • 2 Introduction 26
  • 2.1 Catalyst 26
  • 2.2 Related Reports 27
  • 2.3 Upcoming Related Reports 27
  • 3 Disease Overview 28
  • 3.1 Etiology and Pathophysiology 28
  • 3.1.1 Etiology 28
  • 3.1.2 Pathophysiology 33
  • 3.1.3 Symptoms and Prognosis 34
  • 4 Epidemiology 36
  • 4.1 Disease Background 36
  • 4.2 Risk Factors and Comorbidities 38
  • 4.3 Global Trends 38
  • 4.3.1 Historical Perspective of Vaccination Coverage 39
  • 4.3.2 Laboratory Confirmed Influenza Cases 42
  • 4.3.3 Hospitalization Due to Influenza 42
  • 4.3.4 Influenza Averted Cases 43
  • 4.4 Forecast Methodology 43
  • 4.4.1 Sources Used Tables 44
  • 4.4.2 Forecast Assumptions and Methods 48
  • 4.4.3 Sources Not Used 62
  • 4.5 Epidemiological Forecast for Seasonal Influenza (2015-2025) 63
  • 4.5.1 Seasonal Influenza Vaccination 63
  • 4.5.2 Seasonal Influenza Vaccination Rates 69
  • 4.5.3 Diagnosed Outpatient Influenza-Like Illness Incident Cases 72
  • 4.5.4 Lab Confirmed Incident Cases of Seasonal Influenza 79
  • 4.5.5 Influenza-Related Hospitalized Incident Cases 85
  • 4.5.6 Cases Averted by Seasonal Influenza Vaccinations 91
  • 4.6 Discussion 95
  • 4.6.1 Epidemiological Forecast Insight 95
  • 4.6.2 Limitations of Analysis 96
  • 4.6.3 Strengths of Analysis 97
  • 5 Disease Management 98
  • 5.1 Seasonal Influenza Immunization Policy 98
  • 5.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines 99
  • 5.2 US 101
  • 5.2.1 Influenza Immunization Recommendations and Policies 102
  • 5.2.2 Clinical Practice 105
  • 5.3 France 107
  • 5.3.1 Influenza Immunization Recommendations and Policies 108
  • 5.3.2 Clinical Practice 110
  • 5.4 Germany 111
  • 5.4.1 Influenza Immunization Recommendations and Policies 113
  • 5.4.2 Clinical Practice 115
  • 5.5 Italy 117
  • 5.5.1 Influenza Immunization Recommendations and Policies 119
  • 5.5.2 Clinical Practice 121
  • 5.6 Spain 123
  • 5.6.1 Influenza Immunization Recommendations and Policies 124
  • 5.6.2 Clinical Practice 126
  • 5.7 UK 127
  • 5.7.1 Influenza Immunization Recommendations and Policies 129
  • 5.7.2 Clinical Practice 131
  • 5.8 Japan 133
  • 5.8.1 Influenza Immunization Recommendations and Policies 134
  • 5.8.2 Clinical Practice 135
  • 6 Competitive Assessment 138
  • 6.1 Overview 138
  • 6.2 Product Profiles - Major Brands, Inactivated Vaccines 140
  • 6.2.1 Fluzone Quadrivalent 140
  • 6.2.2 Fluzone High-Dose 146
  • 6.2.3 Fluzone Intradermal 153
  • 6.2.4 Vaxigrip 161
  • 6.2.5 Fluarix Tetra 167
  • 6.2.6 Fluvirin 174
  • 6.2.7 Afluria 179
  • 6.2.8 Agrippal 185
  • 6.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted) 189
  • 6.3.1 Fluad 189
  • 6.4 Product Profiles - Major Brands, Live-Attenuated Vaccines 196
  • 6.4.1 FluMist Quadrivalent 196
  • 6.5 Product Profiles - Major Brands, Cell Cultured Vaccines 204
  • 6.5.1 Flublok 204
  • 6.5.2 Flucelvax 211
  • 6.6 Other Seasonal Influenza Vaccines 218
  • 6.6.1 Influvac 218
  • 6.6.2 Minor Brands 220
  • 7 Unmet Needs and Opportunity Analysis 221
  • 7.1 Overview 221
  • 7.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines 225
  • 7.2.1 Unmet Need 225
  • 7.2.2 Gap Analysis 226
  • 7.2.3 Opportunity 229
  • 7.3 Immunization Policies Targeting Children and Adolescents 230
  • 7.3.1 Unmet Need 230
  • 7.3.2 Gap Analysis 231
  • 7.3.3 Opportunity 231
  • 7.4 Enhanced Vaccine Efficacy in High-Risk Groups 233
  • 7.4.1 Unmet Need 233
  • 7.4.2 Gap Analysis 234
  • 7.4.3 Opportunity 236
  • 7.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies 237
  • 7.5.1 Unmet Need 237
  • 7.5.2 Gap Analysis 238
  • 7.5.3 Opportunity 239
  • 7.6 Improving the Cost-Effectiveness of Influenza Vaccines 240
  • 7.6.1 Unmet Need 240
  • 7.6.2 Gap Analysis 241
  • 7.6.3 Opportunity 242
  • 7.7 Vaccines with Broader Influenza Strain Coverage 243
  • 7.7.1 Unmet Need 243
  • 7.7.2 Gap Analysis 244
  • 7.7.3 Opportunity 245
  • 7.8 Improved Vaccine Safety Profile 246
  • 7.8.1 Unmet Need 246
  • 7.8.2 Gap Analysis 247
  • 7.8.3 Opportunity 248
  • 8 Pipeline Assessment 249
  • 8.1 Overview 249
  • 8.2 Promising Vaccines in Clinical Development 250
  • 8.2.1 Seasonal Influenza VLP Vaccine 255
  • 8.2.2 VN-100 264
  • 8.2.3 Quadrivalent Seasonal Influenza VLP Vaccine 272
  • 8.3 Promising Vaccines in Early-Stage Development 280
  • 8.3.1 FLU-v 281
  • 8.3.2 M-001 282
  • 8.3.3 TAK-850 283
  • 8.3.4 VAX-2012Q 283
  • 8.4 Other Vaccines in Development Outside the 7MM 284
  • 9 Current and Future Players 285
  • 9.1 Overview 285
  • 9.2 Trends in Corporate Strategy 289
  • 9.3 Company Profiles - Major Players 292
  • 9.3.1 Sanofi 292
  • 9.3.2 CSL Limited (Seqirus) 294
  • 9.3.3 GlaxoSmithKline 296
  • 9.3.4 AstraZeneca (MedImmune) 297
  • 9.3.5 Protein Sciences Corporation 300
  • 9.3.6 Mitsubishi Tanabe Pharma 302
  • 9.3.7 Novavax 303
  • 9.4 Other Companies 305
  • 9.4.1 Mylan 305
  • 9.4.2 Daiichi Sankyo 306
  • 10 Market Outlook 307
  • 10.1 Global Markets 307
  • 10.1.1 Forecast 307
  • 10.1.2 Drivers and Barriers - Global Issues 313
  • 10.2 US 314
  • 10.2.1 Forecast 314
  • 10.2.2 Key Events 321
  • 10.2.3 Drivers and Barriers 322
  • 10.3 France 323
  • 10.3.1 Forecast 323
  • 10.3.2 Key Events 327
  • 10.3.3 Drivers and Barriers 327
  • 10.4 Germany 328
  • 10.4.1 Forecast 328
  • 10.4.2 Key Events 332
  • 10.4.3 Drivers and Barriers 332
  • 10.5 Italy 333
  • 10.5.1 Forecast 333
  • 10.5.2 Key Events 337
  • 10.5.3 Drivers and Barriers 338
  • 10.6 Spain 339
  • 10.6.1 Forecast 339
  • 10.6.2 Key Events 343
  • 10.6.3 Drivers and Barriers 343
  • 10.7 United Kingdom 344
  • 10.7.1 Forecast 344
  • 10.7.2 Key Events 348
  • 10.7.3 Drivers and Barriers 349
  • 10.8 Japan 349
  • 10.8.1 Forecast 349
  • 10.8.2 Key Events 354
  • 10.8.3 Drivers and Barriers 355
  • 11 Appendix 356
  • 11.1 Bibliography 356
  • 11.2 Abbreviations 394
  • 11.3 Methodology 398
  • 11.4 Forecasting Methodology 398
  • 11.4.1 Vaccine Coverage 398
  • 11.4.2 Vaccines Included 399
  • 11.4.3 Key Launch Dates 399
  • 11.4.4 Influenza Vaccine Tender System Assumptions 400
  • 11.4.5 General Pricing Assumptions 401
  • 11.4.6 Individual Vaccine Assumptions 402
  • 11.4.7 Pricing of Pipeline Agents 410
  • 11.5 Primary Research - KOLs Interviewed for this Report 411
  • 11.6 Primary Research - Prescriber Survey 414
  • 11.7 About the Authors 415
  • 11.7.1 Analyst 415
  • 11.7.2 Therapy Area Director 415
  • 11.7.3 Epidemiologists 416
  • 11.7.4 Director of Epidemiology 417
  • 11.7.5 Global Director of Therapy Analysis and Epidemiology 417
  • 11.8 About GlobalData 418
  • 11.9 Disclaimer 418
  • Seasonal influenza vaccines market will hit $4.3 billion by 2025, says GlobalData

    The seasonal influenza vaccine market across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will rise from $3.1 billion in 2015 to $4.3 billion by 2025, at a compound annual growth rate of 3.3%, according to research and consulting firm GlobalData.

    The company’s latest report states that the main growth drivers during the forecast period will include amendments to the national immunization schedules of the US and the UK, the expansion of egg-based quadrivalent seasonal influenza vaccines across Germany, Italy, France, and Spain, and the transition from egg-based to cell culture-based vaccines.

    Christopher J. Pace, Ph.D., GlobalData’s Director of Infectious Diseases, explains: “For the past few decades, children have not been the focus of season influenza immunization recommendations in developed nations.

    “More recently, developed countries such as the US and the UK have issued expanded recommendations for the vaccination of healthy children and adolescents against seasonal influenza, thereby indirectly protecting high-risk groups such as the elderly and the immunocompromised from disease by disrupting community transmission. This generates a significant new opportunity for market penetration.”

    Quadrivalent influenza vaccines, which contain antigens against two influenza type A and two influenza type B subtypes, offer broader coverage than trivalent (two influenza A and a single influenza B strain) formulations. In 2015, Japan replaced its trivalent, seasonal influenza vaccines with quadrivalent formulations, and it is expected that trivalent vaccines will be virtually absent from the US market within the next five years. Quadrivalent vaccines will also expand throughout Europe by 2025.

    Pace continues: “Although the vaccination rate across the 7MM is anticipated to remain stable during the next decade, the higher price commanded by quadrivalent vaccines and other next-generation immunizations, such as Sanofi’s Fluzone High-Dose and CSL Limited’s Fluad, is expected to drive market growth.

    “In regards to the transition from egg-based to cell culture-based vaccines, 2016 saw CSL Limited launch the first quadrivalent cell culture-based vaccine on the US market indicated for the immunization of children over four years old - Flucelvax. Its novel manufacturing processes decrease production time compared to egg-based vaccine development and also can be administered to individuals who have egg allergies, giving cell culture-based vaccines an important edge in an intensely competitive marketplace.

    “Novavax’s and Mitsubishi Tanabe’s novel virus-like particle vaccines are also anticipated to further revitalize an influenza market that is gradually moving towards the eventual development of a universal seasonal influenza vaccine.”
    - Comments provided by Christopher J. Pace, Ph.D., GlobalData’s Director of Infectious Diseases.
    - Information based on GlobalData’s report: PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025.
    - This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

Please select a license type

Share

Related Products

GlobalDataPharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025Product ThumbnailPharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025, Industry Report available for $10995Product #: 631489
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved